#1 Clinical Trials Search in Europe

Cabergoline

Cabergoline, a dopamine agonist medication, is being extensively studied in clinical trials for its potential benefits in treating various medical conditions. These trials aim to evaluate the drug’s efficacy, safety, and optimal dosing strategies across different patient populations. From pituitary disorders to breast cancer and fertility treatments, researchers are investigating cabergoline’s diverse applications in improving patient outcomes and quality of life.

Table of Contents

What is Cabergoline?

Cabergoline is a medication that belongs to a class of drugs called dopamine agonists. It is primarily used to treat various conditions related to hormonal imbalances and certain types of tumors[1]. Cabergoline is known by several brand names, including Dostinex, Cabaser, and Cabaseril[2]. Other names for this medication include galastop, FCE 21336, and cabergoline diphosphate[2].

How Cabergoline Works

Cabergoline works by mimicking the action of dopamine, a natural chemical in the brain. It activates dopamine receptors, particularly the D2 receptors, which play a role in regulating hormone production and release[1]. By stimulating these receptors, cabergoline can help control the production of certain hormones, such as prolactin, and influence the growth of specific types of tumors[2].

Conditions Treated with Cabergoline

Cabergoline is used to treat several medical conditions, including:

  • Prolactinomas: These are benign (non-cancerous) tumors of the pituitary gland that produce excess prolactin, a hormone involved in milk production[1].
  • Hyperprolactinemia: This condition is characterized by high levels of prolactin in the blood, which can cause various symptoms such as irregular menstrual cycles and infertility[7].
  • Parkinson’s Disease: Although less common, cabergoline may be used in some cases of Parkinson’s disease[7].
  • Acromegaly: This is a hormonal disorder that results from excess growth hormone (GH) production. Cabergoline may be used in combination with other treatments for some patients with acromegaly[5].
  • Cushing’s Disease: This condition is caused by a tumor in the pituitary gland that leads to excessive production of adrenocorticotropic hormone (ACTH). Some studies are investigating the use of cabergoline in treating this condition[6].

Dosage and Administration

The dosage and administration of cabergoline can vary depending on the condition being treated and the individual patient’s response. Generally, cabergoline is taken orally (by mouth) in tablet form. Here are some common dosing regimens:

  • For prolactinomas and hyperprolactinemia: Treatment typically starts with a low dose, such as 0.25 mg twice weekly, and may be gradually increased based on the patient’s response and prolactin levels[7].
  • For prevention of ovarian hyperstimulation syndrome (OHSS) in fertility treatments: A dose of 0.5 mg per day for 8 days, starting on the day of egg retrieval, may be used[8].
  • For acromegaly: When used in combination with other treatments, doses may range from 1 to 3.5 mg per week[5].

It’s important to note that dosages should always be determined and adjusted by a healthcare professional based on individual patient needs and responses.

Potential Side Effects

Like all medications, cabergoline can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Headache
  • Dizziness
  • Fatigue
  • Constipation or diarrhea

In rare cases, more serious side effects can occur. One concern that has been studied is the potential for cardiac valve complications, particularly in patients taking high doses of cabergoline for extended periods[7]. However, this risk appears to be lower in patients taking cabergoline for conditions like prolactinomas, where the doses are typically much lower than those used in Parkinson’s disease treatment.

Ongoing Research and Potential New Uses

Researchers are continually studying cabergoline to understand its effects better and explore potential new uses. Some areas of ongoing research include:

  • Treatment of non-functioning pituitary adenomas: These are tumors in the pituitary gland that don’t produce excess hormones. Studies are investigating whether cabergoline can help shrink these tumors or prevent their growth[2][8].
  • Use in metastatic breast cancer: Some research is exploring whether cabergoline might be effective in treating certain types of breast cancer[3].
  • Prevention of ovarian hyperstimulation syndrome: This is a potential complication of fertility treatments. Studies are looking at whether cabergoline can help prevent this condition[8].
  • Treatment of Cushing’s disease: Researchers are investigating whether cabergoline might be effective in treating this rare hormonal disorder[6].

These ongoing studies highlight the potential for cabergoline to be used in treating a wider range of conditions in the future. However, it’s important to remember that more research is needed before these potential new uses can be confirmed and approved for general use.

Aspect Details
Primary Conditions Studied Prolactinomas, Non-functioning pituitary adenomas, Breast cancer, Ovarian hyperstimulation syndrome, Cushing’s disease, Acromegaly
Main Outcomes Measured Normalization of hormone levels, Tumor shrinkage, Progression-free survival, Pregnancy rates, Recurrence rates
Dosing Strategies Varied across trials: 0.5-12 mg/week, often with gradual dose escalation
Treatment Duration Ranged from 8 days to 130 weeks, depending on the condition and study design
Safety Monitoring Cardiovascular effects, Impulse control disorders, General adverse events
Imaging Techniques Used MRI for tumor size assessment, 3D ultrasound for endometrial vascularity
Combination Therapies Some trials combined cabergoline with other treatments (e.g., octreotide in acromegaly)

FAQ

  • What is cabergoline and how does it work? Cabergoline is a dopamine agonist medication that works by mimicking the effects of dopamine in the body. It primarily acts on dopamine receptors, particularly D2 receptors, to regulate hormone production and other bodily functions.
  • In which medical conditions is cabergoline being studied? Cabergoline is being studied in various conditions, including prolactinomas, non-functioning pituitary adenomas, Cushing's disease, acromegaly, breast cancer, and as a preventive measure for ovarian hyperstimulation syndrome in fertility treatments.
  • What are the potential benefits of cabergoline in treating pituitary tumors? In pituitary tumor treatments, cabergoline may help normalize hormone levels, reduce tumor size, and improve symptoms associated with hormone imbalances. It is being studied for its potential to prevent tumor recurrence after surgery and as a primary treatment option in some cases.
  • How is cabergoline administered in clinical trials? Cabergoline is typically administered orally in tablet form. The dosing regimens vary depending on the condition being treated and the specific trial protocol. Some studies use a gradual dose escalation approach, while others maintain a fixed dose throughout the treatment period.
  • What are some potential side effects of cabergoline being monitored in clinical trials? Common side effects being monitored include nausea, dizziness, and headache. Some trials are also assessing the long-term cardiovascular safety of cabergoline, particularly its potential effects on heart valves. Additionally, researchers are monitoring for rare but serious side effects such as impulse control disorders.

Ongoing Clinical Trials on Cabergoline

  • A Study Testing Cabergoline to Prevent and Treat Episodic Migraine in Patients with Recurring Migraine Headaches

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study of cabergoline compared to dienogest and ethinylestradiol for reducing endometriosis symptoms and lesion size in women with confirmed endometriosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Comparison of Surgical Treatment versus Cabergoline in Patients with Newly Diagnosed Microprolactinomas

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Cabergoline for Pain and Fertility in Women with Endometriosis and Infertility

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Cabergoline for Treating Non-Functioning Pituitary Adenomas in Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

Glossary

  • Prolactinoma: A benign tumor of the pituitary gland that produces excess amounts of the hormone prolactin.
  • Non-functioning pituitary adenoma (NFPA): A type of pituitary tumor that does not produce excess hormones but can cause symptoms due to its size and compression of surrounding structures.
  • Dopamine agonist: A class of drugs that activate dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine.
  • Ovarian hyperstimulation syndrome (OHSS): A potential complication of fertility treatments where the ovaries become swollen and painful due to excessive stimulation.
  • Macroprolactinoma: A large prolactin-secreting tumor of the pituitary gland, typically greater than 10 mm in size.
  • Insulin-like growth factor I (IGF-I): A hormone similar in structure to insulin that plays a crucial role in growth and development.
  • Cushing's disease: A condition caused by a pituitary tumor that leads to excessive production of adrenocorticotropic hormone (ACTH), resulting in high cortisol levels.
  • Acromegaly: A hormonal disorder caused by excess growth hormone production, typically due to a pituitary tumor.
  • Vascularization index (VI): A measure used in ultrasound imaging to assess the presence and density of blood vessels in a tissue.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.

References

  1. https://clinicaltrials.gov/study/NCT01143584
  2. https://clinicaltrials.eu/trial/study-on-cabergoline-for-treating-non-functioning-pituitary-adenomas-in-patients/
  3. https://clinicaltrials.gov/study/NCT01730729
  4. https://clinicaltrials.gov/study/NCT03457389
  5. https://clinicaltrials.gov/study/NCT01014793
  6. https://clinicaltrials.gov/study/NCT00889525
  7. https://clinicaltrials.gov/study/NCT00460616
  8. https://clinicaltrials.gov/study/NCT03271918